Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

Core claims and the evidence behind them

This narrative review answers seven questions on the kidney–brain axis: CKD prevalence in stroke, cerebrorenal mechanisms, subclinical brain abnormalities, cognition, stroke severity/outcomes, management constraints, and dialysis-associated burden Full review text, Lancet Neurology 2014. The strongest quantitative anchors are: (1) pooled incident-stroke risk rising 43% at eGFR <60, attenuating ~30% after risk-factor adjustment in some cohorts; (2) proteinuria conferring +71% stroke risk; (3) post-thrombolysis symptomatic ICH of 7.6% vs 2.4% and mortality 14.2% vs 4.6% with reduced eGFR.

Independent data confirm the graded outcome signal. In 821 acute stroke patients, 1-year mortality climbed from 15.1% (eGFR >60) to 47.5% (eGFR 15–44) on the MDRD equation Yahalom acute-stroke cohort.

Critical appraisal

Strengths. The review integrates large meta-analyses (284,672 people; 140,231 for proteinuria), a clear mechanistic taxonomy, and a practical panel on therapeutic limitations; authors declared no competing interests and funding was public/institutional Funding and conflict disclosures.

Weaknesses and blind spots. No systematic search protocol or PRISMA-style rigor; observational confounding is acknowledged but residual confounding (duration/severity of risk exposure) is under-analyzed. Acute-stroke creatinine is inflated by the stroke itself — the review flags this but prevalence figures (20–46%) remain partly confounded. The Asian vs non-Asian effect heterogeneity (RR 1.96 vs 1.26) may reflect blood-pressure severity, population structure, or collider bias rather than race per se. Notably, post-publication Mendelian randomization supports causality only for albuminuria, not eGFR/CKD per se, which the 2014 framing did not anticipate MR supports albuminuria, not eGFR, for stroke. Conversely, later cohort work extends the review: combined CHF+CKD raises unfavorable post-stroke rehabilitation outcomes ~5.8-fold (HR 5.8, 95% CI 2.5–13.44) versus either alone CHF-CKD post-stroke rehabilitation cohort, and creatinine/cystatin-C sarcopenia indices show a non-linear, threshold-dependent stroke association (inflection SI≈70) CHARLS sarcopenia index and stroke.

What would change the conclusions. Rigorously adjusted cohorts showing no CKD–stroke association after albuminuria adjustment; RCTs in advanced CKD showing anticoagulant/thrombolysis decisions are risk-neutral would undercut the management section. The warfarin-in-dialysis controversy (protection in some registries, harm in others) remains unresolved, so conclusions there should be held with low confidence. The vascular calcification threat to carotid revascularization parallels CAS-vs-CEA trade-offs (higher periprocedural stroke OR 2.43 for stenting vs CEA) CAS vs CEA meta-analysis, but the review does not quantify how CKD shifts this calculus — a genuine gap.

Author Review: Kazunori ToyodaAuthor Review: Toshiharu Ninomiya

 BGPT Paper Review

Study Novelty

A competent early synthesis of the cerebrorenal interaction, but the individual associations (eGFR, proteinuria, stroke) were already established in prior meta-analyses cited within the review itself; the Klotho/FGF23 framing was relatively fresh for 2014.

Scientific Quality

Rigorous citation of pooled analyses with explicit CIs and honest reporting of non-significant adjusted associations; however, it is a narrative (not systematic) review, lacks PRISMA methods, and some registry-derived conclusions (warfarin in dialysis) rest on conflicting observational data the authors treat carefully but cannot resolve.

Study Generality

Spans epidemiology, mechanisms, imaging, cognition, acute management, and dialysis populations across multiple countries; broad cross-disciplinary relevance to neurology and nephrology.

Study Usefulness

Clinically actionable: identifies management constraints (NOAC contraindication, thrombolysis bleeding risk, antihypertensive AKI risk) and sets a research agenda (cerebrorenal interaction) that subsequent MR and cohort studies engaged.

Study Reproducibility

Search strategy is stated (PubMed, terms, cutoff date) but no PRISMA flow, no formal quality scoring of included studies, and no underlying data; as a narrative review, synthesis choices are not fully replicable.

Explanatory Depth

Provides a layered mechanistic model (traditional, non-traditional, uraemia-related, Klotho/FGF23) linking kidney to brain microvasculature, but mechanistic claims are largely inferential from biomarker associations rather than interventional evidence.